Open access

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Predicting Treatment Response and Survival Outcomes Among Patients with Solid Tumors: A Prospective Observational Study

Vishal Mehrotra Anurag Singh Swarnava Chanda Nashra Afaq Bushra Khalid Madhu Yadav Zahid Manzoor Khanday

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 20 references

Abstract

Background: Cancer-associated inflammation plays a crucial role in tumor initiation, progression, angiogenesis, metastasis

DOI Semantic Scholar

Read PDF

Similar papers

Review Open access Jan 2026

Correction to “Neutrophil‐Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR‐TKIs: A Systematic Review and Meta‐Analysis”

[This corrects the article DOI: 10.1155/2021/6688346.].

Unknown authors · Journal of Oncology · 0 citations

Meta-analysis Open access Sep 2026

Sex, Timing, and Outcomes of Curative-Intent Immunotherapy

This systematic review and meta-analysis evaluates associations between immune checkpoint inhibitors and survival outcomes by patient sex and timing of administration among patients receiving curative treatment for solid tumors.

Anne-Murielle Hollinger, C. Gerard, V. Andreas et al. · JAMA Network Open · 0 citations

Review Open access Aug 2026

Correction: Prognostic significance of inflammation-based markers in nasopharyngeal carcinoma: a systematic review and meta-analysis

[This corrects the article DOI: 10.3389/fonc.2026.1806939.].

Ya-Jun Wang, Leyu Zhang, Qian-Yu Liu et al. · Frontiers in Oncology · 0 citations

Open access Sep 2026

Correction: Iinuma et al. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J. Clin. Med. 2021, 10, 5325

Error in Figure [...].

K. Iinuma, Torai Enomoto, K. Kawada et al. · Journal of Clinical Medicine · 0 citations

Open access Sep 2026

AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer

[This corrects the article DOI: 10.1016/j.omton.2026.201253.].

Tatsuki Ikoma, K. Araki, M. Kitagawa et al. · Molecular therapy. Oncology · 0 citations

Open access Aug 2026

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".

Not available.

Curtis Marcoux, D. White · Haematologica · 0 citations